Skip to Content

'
Timothy C Thompson, Ph.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Genitourinary Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Director of Prostate Cancer Basic Science Research, Department of Genitourinary Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Joan and Stanford Alexander Distinguished Chair for Prostate Cancer Research, Department of Genitourinary Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1985 University of Colorado, Boulder, CO, PhD, Pharmaceutical Sciences-Pharmacology
1974 Indiana University, Bloomington, IN, BA, Biological Sciences

Postgraduate Training

1985-1988 Research Fellowship, Imperial Cancer Research Fund, London, United Kingdom

Selected Publications

Peer-Reviewed Original Research Articles

1. Thompson TC, Li L. Anti-androgen receptor therapy-mediated derepressed genes: new targets for castration-resistant prostate cancer. Oncotarget. In Press.
2. Karanika S, Karantanos T, Li L, Corn PG, Thompson TC. DNA damage response and prostate cancer: defects, regulation and therapeutic implications. Oncogene. In Press. NIHMSID: NIHMS609232.
3. Thompson TC, Karanika S,. Novel Anti-androgen Receptor Signaling Agents: Understanding the Mechanisms of Resistance. Asian Journal of Urology. In Press.
4. Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, Karanika S, Wang J, Yin J, Shah PK, Takahiro H, Dobashi M, Zhang W, Efstathiou E, Maity SN, Aparicio AM, Li Ning Tapia EM, Troncoso P, Broom B, Xiao L, Lee HS, Lee JS, Corn PG, Navone N, Thompson TC. Targeting Poly(ADP-Ribose) Polymerase and the c-Myb-Regulated DNA Damage Response Pathway in Castration-Resistant Prostate Cancer. Sci Signal 7(326):ra47, 5/20/2014. e-Pub 5/20/2014. PMID: 24847116.
5. Karantanos T, Tanimoto R, Edamura K, Hirayama T, Yang G, Golstov AA, Wang J, Kurosaka S, Park S, Thompson TC. Systemic GLIPR1-ΔTM protein as a novel therapeutic approach for prostate cancer. Int J Cancer 134(8):2003-13, 4/15/2014. e-Pub 11/1/2013. PMCID: PMC3942887.
6. Fujita T, Satoh T, Timme TL, Hirayama T, Zhu JX, Kusaka N, Naruishi K, Yang G, Goltsov A, Wang J, Vlachaki MT, Teh BS, Brian Butler E, Thompson TC. Combined therapeutic effects of adenoviral vector-mediated GLIPR1 gene therapy and radiotherapy in prostate and bladder cancer models. Urol Oncol 32(2):92-100, 2/2014. e-Pub 2/20/2013. PMCID: PMC3871954.
7. Tan X, Wang Y, Han Y, Chang W, Su T, Hou J, Xu D, Yu Y, Ma W, Thompson TC, Cao G. Genetic variation in the GSTM3 promoter confer risk and prognosis of renal cell carcinoma by reducing gene expression. Br J Cancer 109(12):3105-15. doi: 10.1038/bjc.2013.669, 12/10/2013. e-Pub 10/24/2013. PMCID: PMC3859948.
8. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanicsms of castrate resistance and novel therapeutic approaches. Oncogene 32(49):doi: 10.1038/onc.2013.206, 12/5/2013. e-Pub 6/10/2013. PMCID: PMC3908870.
9. Ayala G, Morello M, Frolov A, You S, Li R, Rosati F, Bartolucci G, Danza G, Adam RM, Thompson TC, Lisanti MP, Freeman MR, Di Vizio D. Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumor progression. J Pathol 231(1):77-87, 9/2013. e-Pub 7/8/2013. PMCID: PMC3978784.
10. Karantanos T, Thompson TC. GEMMs shine a light on resistance to androgen deprivation therapy for prostate cancer. Cancer Cell 24(1):11-13, 7/8/2013. PMCID: PMC3881957.
11. Li L, Yang G, Ren C, Tanimoto R, Hirayama T, Wang J, Hawke D, Kim SM, Lee JS, Goltsov AA, Park S, Ittmann MM, Troncoso P, Thompson TC. Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2. Mol Oncol 7(3):484-96, 6/2013. e-Pub 12/31/2012. PMCID: PMC3907183.
12. Tahir SA, Kurosaka S, Tanimoto R, Goltsov AA, Park S, Thompson TC. Serum caveolin-1 as a biomarker of drug response and therapeutic target in association with tyrosine kinase inhibitor treatment in prostate cancer models. Cancer Biol Ther 14(2):117-26, 2/2013. e-Pub 10/31/2012. PMCID: PMC3571993.
13. Yang G, Goltsov AA, Ren C, Kurosaka S, Edamura K, Logothetis R, DeMayo FJ, Troncoso P, Blando J, DiGiovanni J, Thompson TC. Caveolin-1 upregulation contributes to c-myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer. Mol Cancer Res 10(2):218-29, 2/2012. e-Pub 12/5/2011. PMCID: PMC3908884.
14. Li L, Ren C, Yang G, Fattah EA, Goltsov AA, Kim SM, Lee JS, Park S, Demayo FJ, Ittmann MM, Troncoso P, Thompson TC. GLIPR1 suppressess prostate cancer through targeted oncoprotein destruction. Cancer Res 71(24):7694-704, 12/15/2011. e-Pub 10/24/2011. PMCID: PMC3813470.
15. Sonpavde G, Thompson TC, Jain RK, Ayala GE, Kurosaka S, Edamura K, Tabata K, Ren C, Goltsov AA, Mims MP, Hayes TG, Ittmann MM, Wheeler TM, Gee A, Miles BJ, Kadmon D. GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res 17(22):7174-82, 11/15/2011. e-Pub 9/20/2011. PMCID: PMC3865786.
16. Floryk D, Kurosaka S, Tanimoto R, Yang G, Goltsov A, Park S, Thompson TC. Castration-induced changes in mouse epididymal white adipose tissue molecular and cellular endocrinology. Mol Cell Endocrinol 345(1-2):58-67, 10/15/2011. e-Pub 7/12/2011. PMCID: PMC3867123.
17. Tabata K, Kurosaka S, Watanabe M, Edamura K, Satoh T, Yang G, Abdelfattah E, Wang J, Goltsov A, Floryk D, Thompson TC. Tumor growth and metastasis suppression by Glipr1 gene-modified macrophages in a metastatic prostate cancer model. Gene Ther 18(10):969-78, 10/2011. e-Pub 4/21/2011. PMCID: PMC3881531.
18. Thompson TC. Turning reciprocal feedback regulation into combination therapy. Cancer Cell 19(19):697-699, 6/14/2011. PMID: 21665144.
19. Gao Y, Ishiyama H, Sun M, Brinkman KL, Wang X, Zhu Z, Mai W, Huang Y, Floryk D, Ittmann M, Thompson TC, Butler EB, Xu B, The BS. The akylphospholipid, perifosine, radiosensitizes prostate cancer cells both in vitro and in vivo. Radiat Oncol(15):6-39, 4/2011.
20. Yang G, Park S, Cao G, Goltsov A, Ren C, Truong LD, Demayo F, Thompson TC. MMTV promoter-regulated caveolin-1 overexpression yields defective parenchymal epithelia in multiple exocrine organs of transgenic mice. Exp Mol Pathol 89(1):9-19, 8/2010. e-Pub 4/22/2010. PMCID: PMC3881545.
21. Thompson TC. Glioma pathogenesis-related protein 1: tumor-suppressor activities and therapeutic potential. Yonsei Med J 51(4):479-83, 7/2010. PMCID: PMC2880257.
22. Langeberg WJ, Tahir SA, Feng Z, Kwon EM, Ostrander EA, Thompson TC, Stanford JL. Association of caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes. Prostate 70(9):1020-35, 6/15/2010. PMCID: PMC2875326.
23. Thompson TC. Grappling with the androgen receptor: a new approach for treating advanced prostate cancer. Cancer Cell 17(6):525-6, 6/15/2010. PMCID: PMC3929402.
24. Thompson TC, Tahir SA, Li L, Watanabe M, Naruishi K, Yang G, Kadmon D, Logothetis CJ, Troncoso P, Ren C, Goltsov A, Park S. The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic Dis 13(1):6-11, 3/2010. e-Pub 7/7/2009. PMCID: PMC2887695.
25. Corn PG, Thompson TC. Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit. Cancer Manag Res 2:111-122, 2010. e-Pub 5/10/2010. PMCID: PMC3004586.
26. Tahir SA, Park S, Thompson TC. Caveolin-1 regulates VEGF-stimulated angiogenic activities in prostate cancer and endothelial cells. Cancer Biol Ther 8(23):2286-96, 12/2009. e-Pub 12/19/2009. PMCID: PMC2887683.
27. Li L, Ren C, Yang G, Goltsov AA, Tabata K, Thompson TC. Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells. Mol Cancer Res 7(11):1781-91, 11/2009. e-Pub 11/10/2009. PMCID: PMC3881562.
28. Watanabe M, Yang G, Cao G, Tahir SA, Naruishi K, Tabata K, Fattah EA, Rajagopalan K, Timme TL, Park S, Kurosaka S, Edamura K, Tanimoto R, Demayo FJ, Goltsov AA, Thompson TC. Functional analysis of secreted caveolin-1 in mouse models of prostate cancer progression. Mol Cancer Res 7(9):1446-55, 9/2009. e-Pub 9/8/2009. PMCID: PMC2887686.
29. Tabata K, Watanabe M, Naruishi K, Edamura K, Satoh T, Yang G, Abdel Fattah E, Wang J, Goltsov A, Floryk D, Soni SD, Kadmon D, Thompson TC. Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer. Prostate Cancer Prostatic Dis 12(3):301-9, 2009. e-Pub 12/23/2008. PMID: 19104507.
30. Ayala GE, Dai H, Powell M, Li R, Ding Y, Wheeler TM, Shine D, Kadmon D, Thompson T, Miles BJ, Ittmann MM, Rowley D. Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin Cancer Res 14(23):7593-603, 12/1/2008. PMID: 19047084.
31. Floryk D, Thompson TC. Antiproliferative effects of AVN944, a novel inosine 5-monophosphate dehydrogenase inhibitor, in prostate cancer cells. Int J Cancer 123(10):2294-302, 11/15/2008. PMCID: PMC2887704.
32. Ayala G, Yan J, Li R, Ding Y, Thompson TC, Mims MP, Hayes TG, MacDonnell V, Lynch RG, Frolov A, Miles BJ, Wheeler TM, Harper JW, Tsai MJ, Ittmann MM, Kadmon D. Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated akt. Clin Cancer Res 14(22):7511-8, 11/15/2008. PMCID: PMC2820291.
33. Floryk D, Thompson TC. Perifosine induces differentiation and cell death in prostate cancer cells. Cancer Lett 266(2):216-26, 8/8/2008. e-Pub 4/18/2008. PMCID: PMC2525810.
34. Wang H, Thompson TC. Gene-modified bone marrow cell therapy for prostate cancer. Gene Ther 15(10):787-96, 5/2008. e-Pub 4/3/2008. PMID: 18385769.
35. Yang G, Timme TL, Naruishi K, Fujita T, Fattah el MA, Cao G, Rajagopalan K, Rajocopolan K, Troung LD, Thompson TC. Mice with cav-1 gene disruption have benign stromal lesions and compromised epithelial differentiation. Exp Mol Pathol 84(2):131-40, 4/2008. e-Pub 8/31/2007. PMID: 18358473.
36. Tahir SA, Yang G, Goltsov AA, Watanabe M, Tabata K, Addai J, Fattah el MA, Kadmon D, Thompson TC. Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer. Cancer Res 68(3):731-9, 2/1/2008. PMID: 18245473.
37. Li L, Abdel Fattah E, Cao G, Ren C, Yang G, Goltsov AA, Chinault AC, Cai WW, Timme TL, Thompson TC. Glioma pathogenesis-related protein 1 exerts tumor suppressor activities through proapoptotic reactive oxygen species-c-Jun-NH2 kinase signaling. Cancer Res 68(2):434-43, 1/15/2008. PMID: 18199537.
38. Tahir SA, Frolov A, Hayes TG, Mims MP, Miles BJ, Lerner SP, Wheeler TM, Ayala G, Thompson TC, Kadmon D. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res 12(16):4872-5, 8/2006. PMID: 16914574.
39. Ayala G, Satoh T, Li R, Shalev M, Gdor Y, Aguilar-Cordova E, Frolov A, Wheeler TM, Miles BJ, Rauen K, Teh BS, Butler EB, Thompson TC, Kadmon D. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther 13(4):716-28, 4/2006. PMID: 16480930.
40. Ayala GE, Dai H, Li R, Ittmann M, Thompson TC, Rowley D, Wheeler TM. Bystin in perineural invasion of prostate cancer. Prostate 66(3):266-72, 2/15/2006. PMID: 16245277.
41. Tetzlaff MT, Teh BS, Timme TL, Fujita T, Satoh T, Tabata K, Mai WY, Vlachaki MT, Amato RJ, Kadmon D, Miles BJ, Ayala G, Wheeler TM, Aguilar-Cordova E, Thompson TC, Butler EB. Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancer. Technol Cancer Res Treat 5(1):23-36, 2/2006. PMID: 16417399.
42. Saika T, Kusaka N, Mouraviev V, Satoh T, Kumon H, Timme TL, Thompson TC. Therapeutic effects of adoptive splenocyte transfer following in situ AdIL-12 gene therapy in a mouse prostate cancer model. Cancer Gene Ther 13(1):91-8, 1/1/2006. PMID: 16052232.
43. Koh MS, Ittmann M, Kadmon D, Thompson TC, Leach FS. CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer. Cancer Biol Ther 5(1):78-83, 1/2006. PMID: 16357515.
44. Dai H, Li R, Wheeler T, Diaz de Vivar A, Frolov A, Tahir S, Agoulnik I, Thompson T, Rowley D, Ayala G. Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate 65(3):276-86, 11/1/2005. PMID: 16015593.
45. Haqq C, Li R, Khodabakhsh D, Frolov A, Ginzinger D, Thompson T, Wheeler T, Carroll P, Ayala G. Ethnic and racial differences in prostate stromal estrogen receptor alpha. Prostate 65(2):101-9, 10/1/2005. PMID: 15880569.
46. Li L, Ittmann MM, Ayala G, Tsai MJ, Amato RJ, Wheeler TM, Miles BJ, Kadmon D, Thompson TC. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis 8(2):108-18, 2005. PMID: 15724144.
47. Li L, Ren CH, Tahir SA, Ren C, Thompson TC. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 23(24):9389-404, 12/2003. PMID: 14645548.
48. Satoh T, Timme TL, Saika T, Ebara S, Yang G, Wang J, Ren C, Kusaka N, Mouraviev V, Thompson TC. Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer. Hum Gene Ther 14(2):91-101, 1/20/2003. PMID: 12614561.
49. Ren C, Li L, Goltsov AA, Timme TL, Tahir SA, Wang J, Garza L, Chinault AC, Thompson TC. mRTVP-1, a novel p53 target gene with proapoptotic activities. Mol Cell Biol 22(10):3345-57, 5/2002. PMID: 11971968.
50. Li L, Yang G, Ebara S, Satoh T, Nasu Y, Timme TL, Ren C, Wang J, Tahir SA, Thompson TC. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res 61(11):4386-92, 6/2001. PMID: 11389065.
51. Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, Li L, Goltsov A, Ittmann M, Morrisett JD, Thompson TC. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 61(10):3882-5, 5/2001. PMID: 11358800.
52. Yang G, Truong LD, Wheeler TM, Thompson TC. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res 59(22):5719-23, 11/1999. PMID: 10582690.
53. Nasu Y, Timme TL, Yang G, Bangma CH, Li L, Ren C, Park SH, DeLeon M, Wang J, Thompson TC. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med 4(9):1062-4, 9/1998. PMID: 9734401.
54. Eastham JA, Truong LD, Rogers E, Kattan M, Flanders KC, Scardino PT, Thompson TC. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest 73(5):628-35, 11/1995. PMID: 7474936.
55. Eastham JA, Stapleton AM, Gousse AE, Timme TL, Yang G, Slawin KM, Wheeler TM, Scardino PT, Thompson TC. Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res 1(10):1111-8, 10/1995. PMID: 9815901.
56. Baley PA, Yoshida K, Qian W, Sehgal I, Thompson TC. Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer. J Steroid Biochem Mol Biol 52(5):403-13, 5/1995. PMID: 7538321.
57. Thompson TC, Park SH, Timme TL, Ren C, Eastham JA, Donehower LA, Bradley A, Kadmon D, Yang G. Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. Oncogene 10(5):869-79, 3/2/1995. PMID: 7534899.
58. Timme TL, Truong LD, Slawin KM, Kadmon D, Park SH, Thompson TC. Mesenchymal-epithelial interactions and transforming growth factor-beta 1 expression during normal and abnormal prostatic growth. Microsc Res Tech 30(4):333-41, 3/1/1995. PMID: 7541677.
59. Greene DR, Taylor SR, Aihara M, Yoshida K, Egawa S, Park SH, Timme TL, Yang G, Scardino PT, Thompson TC. DNA ploidy and clonal selection in ras + myc-induced mouse prostate cancer. Int J Cancer 60(3):395-9, 1/27/1995. PMID: 7829250.
60. Aihara M, Scardino PT, Truong LD, Wheeler TM, Goad JR, Yang G, Thompson TC. The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostate. Cancer 75(2):522-9, 1/15/1995. PMID: 7529128.
61. Donehower LA, Harvey M, vogel H, McArthur MJ, Montgomery Jr CA, park SH, Thompson TC, Ford RJ and Bradley A. Effects of genetic background of tumorigenesis in p53-deficient mice. Mol Carcinog 14:16-22, 1995.
62. Eastham JA, Hall SJ, Sehgal I, Wang J, Connel-Crowley L, Elledge SJ, Zhang W-W, Harper, JW and Thompson TC. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 55:5151-5155, 1995.
63. Thompson TC, Timme TL, Park SH, Ren C, Baley PA, Eastham JA, Sehgal I, Yang G and Kadmon D. Tissue and cell-cell interactions in prostate cancer progression. Cancer 75(Suppl):1885-1891, 1995.
64. Timme TL, Yang G, Truong LD, Kadmon D, Park SH, Thompson TC. Transforming growth factor-beta localization during mouse prostate morphogenesis and in prostatic growth abnormalities. World J Urol 13(6):324-8, 1995. PMID: 9116750.
65. Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 152(5 Pt 2):1843-9, 11/1994. PMID: 7523732.
66. Timme TL, Thompson TC. Rapid allelotype analysis of p53 knockout mice. Biotechniques 17(3):460, 462-3, 9/1994. PMID: 7818898.
67. Aihara M, Truong LD, Dunn JK, Wheeler TM, Scardino PT, Thompson TC. Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Hum Pathol 25(8):797-801, 8/1994. PMID: 7520020.
68. Greene DR, Rogers E, Wessels EC, Wheeler TM, Taylor SR, Santucci RA, Thompson TC, Scardino PT. Some small prostate cancers are nondiploid by nuclear image analysis: correlation of deoxyribonucleic acid ploidy status and pathological features. J Urol 151(5):1301-7, 5/1994. PMID: 8158775.
69. Timme TL, Truong LD, Merz VW, Krebs T, Kadmon D, Flanders KC, Park SH, Thompson TC. Mesenchymal-epithelial interactions and transforming growth factor-beta expression during mouse prostate morphogenesis. Endocrinology 134(3):1039-45, 3/1994. PMID: 8119140.
70. Wheeler TM, Rogers E, Aihara M, Scardino PT, Thompson TC. Apoptotic index as a biomarker in prostatic intraepithelial neoplasia (PIN) and prostate cancer. J Cell Biochem Suppl 19:202-7, 1994. PMID: 7823593.
71. Slawin K, Kadmon D, Park SH, Scardino PT, Anzano M, Sporn MB, Thompson TC. Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system. Cancer Res 53(19):4461-5, 10/1/1993. PMID: 8402613.
72. Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH. Transgenic models for the study of prostate cancer. Cancer 71(3 Suppl):1165-71, 2/1/1993. PMID: 8428340.
73. Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC. Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study. Hum Pathol 24(1):4-9, 1/1993. PMID: 7678092.
74. Thompson TC, Timme TL, Kadmon D, Park SH, Egawa S, Yoshida K. Genetic predisposition and mesenchymal-epithelial interactions in ras+myc-induced carcinogenesis in reconstituted mouse prostate. Mol Carcinog 7(3):165-79, 1993. PMID: 8489712.
75. Thompson TC, Egawa S, Kadmon D, Miller GJ, Timme TL, Scardino PT, Park SH. Androgen sensitivity and gene expression in ras + myc-induced mouse prostate carcinomas. J Steroid Biochem Mol Biol 43(1-3):79-85, 9/1992. PMID: 1525069.
76. Lu X, Park SH, Thompson TC, Lane DP. Ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell 70(1):153-61, 7/10/1992. PMID: 1623518.
77. Egawa S, Kadmon D, Miller GJ, Scardino PT, Thompson TC. Alterations in mRNA levels for growth-related genes after transplantation into castrated hosts in oncogene-induced clonal mouse prostate carcinoma. Mol Carcinog 5(1):52-61, 1992. PMID: 1543541.
78. Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH. Transforming growth factor-β1 as a biomarker for prostate cancer. J Cell Biochem Suppl 16H:54-61, 1992. PMID: 1289674.
79. Kadmon D, Thompson TC, Lynch GR, Scardino PT. Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol 146(2):358-61, 8/1991. PMID: 1856931.
80. Merz VW, Miller GJ, Krebs T, Timme TL, Kadmon D, Park SH, Egawa S, Scardino PT, Thompson TC. Elevated transforming growth factor-β1 and β3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate: evidence for a paracrine role during progression. Mol Endocrinol 5(4):503-13, 4/1991. PMID: 1922083.
81. Thompson TC, Kadmon D, Timme TL, Merz VW, Egawa S, Krebs T, Scardino PT, Park SH. Experimental oncogene induced prostate cancer. Cancer Surv 11:55-71, 1991. PMID: 1726789.
82. Thompson TC. Growth factors and oncogenes in prostate cancer. Cancer Cells 2(11):345-54, 11/1990. PMID: 2282250.
83. Thompson TC, Southgate J, Kitchener G, Land H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 56(6):917-30, 3/1989. PMID: 2538247.
84. Compere SJ, Baldacci P, Sharpe AH, Thompson TC, Land H and Jaenisch R. The ras and myc oncogenes cooperate in tumor induction in many tissues when introduced into midgestation mouse embryos by retroviral vectors. Proc Natl Acad Sci USA 86:2224-2228, 1989.
85. Mills JS, Needham M, Thompson TC, Parker MG. Androgen-regulated expression of secretory protein synthesis in mouse ventral prostate. Mol Cell Endocrinol 53(1-2):111-8, 9/1987. PMID: 3666286.
86. Thompson TC, Zhau HY, Chung LW. Catecholamines are involved in the growth and expression of prostatic binding protein by rat ventral prostatic tissues. Prog Clin Biol Res 239:239-48, 1987. PMID: 2821548.
87. Thompson TC, Cunha GR, Shannon JM, Chung LW. Androgen-induced biochemical responses in epithelium lacking androgen receptors: characterization of androgen receptors in the mesenchymal derivative of urogenital sinus. J Steroid Biochem 25(5A):627-34, 11/1986. PMID: 3795942.
88. Thompson TC, Chung LW. Regulation of overgrowth and expression of prostatic binding protein in rat chimeric prostate gland. Endocrinology 118(6):2437-44, 6/1986. PMID: 2422020.
89. Thompson TC and Chung LWK. Evidence for a urogenital sinus-derived growth factor(s). Ann NY Acad Sci 438:582-5, 1985.
90. Chung LWK, Matsuura J, Rocco AK, Thompson TC, Miller GJ and Runner MN. Tissue interactions and prostatic growth. Ann NY Acad Sci 438:582-585, 1985.
91. Thompson TC, Chung LW. Extraction of nuclear androgen receptors by sodium molybdate from normal rat prostates and prostatic tumors. Cancer Res 44(3):1019-26, 3/1984. PMID: 6692389.
92. Chung LW, Matsuura J, Rocco AK, Thompson TC, Miller GJ, Runner MN. A new mouse model for prostatic hyperplasia: induction of adult prostatic overgrowth by fetal urogenital sinus implants. Prog Clin Biol Res 145:291-306, 1984. PMID: 6201880.
93. Thompson TC, Chung LW. Evidence for a soluble fetal urogenital sinus-derived growth factor(s). Ann N Y Acad Sci 438:582-5, 1984. PMID: 6085457.
94. Neubauer BL, Chung LW, McCormick KA, Taguchi O, Thompson TC, Cunha GR. Epithelial-mesenchymal interactions in prostatic development. II. Biochemical observations of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder. J Cell Biol 96(6):1671-6, 6/1983. PMID: 6853598.
95. Chung LW, Matsuura J, Thompson TC, Chao RC. A new approach to regulation of prostatic growth: interactions between embryonic urogenital sinuses and adult prostate in situ. Proc West Pharmacol Soc 25:141-5, 1982. PMID: 6889738.
96. Chung LW, Thompson TC, Breitweiser K. Sensitive biochemical methods to distinguish hormone dependent and independent Dunning tumors of prostatic origin. Proc West Pharmacol Soc 24:305-10, 1981. PMID: 6265951.
97. Li L, Chang W, Yang G, Ren C, Park S, Takahiro H, Troncoso P, Broom B, Lee HS, Lee JS, Thompson TC. Activation of c-Myb and a c-Myb-regulated DNA damage response gene program contributes to drug resistance in prostate cancer. Cancer Discovery. Submitted.
98. Karantanos T, Kurosaka S, Hirayama T, Yang G, Karanika S, Park S, Wang J, Golstov A, Li L, Thompson TC. GLIPR1-ΔTM Synergizes with Docetaxel in Cell Killing and Inhibits Resistance to Docetaxel in Prostate Cancer Cells. Molecular Cancer. Submitted.

Editorials

1. Thompson TC, Kadmon D, Timme TL, Egawa S, Krebs T, Merz VW, Park SH, Ripoll E, Scardino PT. Experimental, oncogene-induced prostate cancer. Baylor Urologic Update, 6/1991.
2. Tindall DJ, Thompson TC, Buttyan R. Molecular biology: understanding methods and applications. AUA Annual Meeting, Text for Postgraduate Course, 1990.
3. Thompson TC. Uncoupling of growth and differentiation in rat ventral prostate: Involvement of 5-hydroxytryptamine and norepinephrine, 1985.
Other Articles
1. Kadmon D and Thompson TC. Mechanisms of developing androgen independence in carcinoma of the prostate. PROspectives: Contemporary Issues in Managing Prostatic Disease 5:1-3, 1995.
2. Thompson TC, Timme TL, Egawa S, Yoshida K, Park SH, Baley PA, Slawin K and Kadmon D. Mesenchymal-epithelial interactions during prostate carcinogenesis. Fundamental Approaches to the Diagnosis and Treatment of Prostate Cancer and BPH: Proceedings of the Fifth Tokyo Symposium:105-108, 1994.
3. Thompson TC, Slawin K, Kadmon D, Park SH, Timme TL, Yoshida K, Ren C, Truong LD, Scardino PT and Eastham JA. Molecular pathways in prostate carcinogenesis. Fundamental Approaches to the Diagnosis and Treatment of Prostate Cancer and BPH: Proceedings of the Fifth Tokyo Symposium:145-149, 1994.
4. Thompson TC, Timme TL, Egawa S, Park SH, Kadmon D, Yoshida K, Scardino PT and Mottaz A. Genetic differences in susceptibility to ras+myc-induced carcinogenesis in reconstituted mouse prostate involves mesenchymal-epithelial interactions. Progress in Endocrinology: Proceedings of Ninth International Congress on Endocrinology, 1993.
5. Chung LWK, Thompson TC, Chao HY, Bell C and Ruth JA. Catecholamines are involved in stromal-epithelial interactions in rat ventral prostate gland. Second NIADDK Symposium on Benign Prostatic Hyperplasia, 5/1985.
6. Chung LWK, Matsuura J, Rocco AK, Thompson TC, Miller GJ, and Runner MN. A new mouse model for prostatic hyperplasia: induction of adult prostatic overgrowth by fetal urogenital sinus implants. New Approaches to The Study of Benign Prostatic Hyperplasia. BPH Workshop, 1984.

Abstracts

1. Thompson TC, Li L, Yang G, Ren C, Chang W, Hirayama T, Kim SM, Lee JS, Troncoso P, Park S. c-Myb and its targets as drivers in prostate cancer progression. The 6th Severence- MD Anderson Cancer Center Joint Symposium - "Personalized Cancer Therapy and Prevention.", 10/2012.
2. Elliott, MH, Dozmorov M, Li X, Iqbal H, McClellan M, Wren JD, Cao G, Thompson TC, Ueffing M, Jauck SM. Insights into caveolin-1 function: quantitative proteomic analysis of a novel retina-specific knockout mouse model. ARVO 2012, Translational Research: Seeing the Possibilities, 12/2011.
3. Thompson TC, Li L, Ren C, Yang G, Goltsov A, Abdel-Fattah E. Glioma pathogenesis-related protein 1, a tumor suppressor that stimulates oncoprotein destruction. 7th Annual National Symposium on Prostate Cancer, Clark Atlanta University, 5/2011.
4. Thompson TC, Li L, Ren C, Yang G, Goltsov A, Abdel-Fattah E. GLIPR1 suppresses prostate cancer through targeted oncoprotein destruction. The 5th Severence-MD Anderson Cancer Center Joint Symposium- "Personalized Cancer Therapy and Prevention", 5/2011.
5. Carthon B, Tahir S, Yang G, Wan X, Yang J, Tanimoto R, Kurosaka S, Park S, Goltsov A, Traoncoso P, Araujo J, Wen S, Gallick G, Navone N, Logothetis C, Thompson T. Caveolin-1 as a biomarker of osteoblast activation and Src family kinase/Abl inhibition in castrate-resistant prostate cancer. United States Department of Defense-Innovative Minds in Prostate Cancer Today (DOD-IMPACT) Conference, March 9-12, 2011, 3/2011.
6. Thompson TC, Li L, Ren C, Yang G, Goltsov A, Abdelfattah E-M. Glioma pathogenesis-relate protein 1, a tumor suppressor that stimulates oncoprotein destruction. United States Departmetn of Defense-Innovative Minds in Prostate CAncer Today (DOD-IMPACT) Conference, March 9-12, 2011, 3/2011.
7. Carthon B, Tahir S, Araujo J, Wen S, Gallick G, Logothetis C,Thompson T. Caveolin-1 as a biomarker of Src kinase inhibition in castration resistant prostate cancer. 2011 ASCO Genitourinary Cancers Symposium, Feb 17-19, 2011, 2/2011.
8. Carthon B, Tahir S, Araujo J, Wen S, Gallick G, Logothetis C, Thompson T. Serum Caveolin-1 as a biomarker of Src kinase inhibition in castration resistant prostate cancer. Innovations in Cancer Research and Prevention and Research Conference, Nov 17-19, 2010, 11/2010.
9. Tahir SA, Kurosaka S, Tanimoto R, Goltsov A, Park SH, Thompson TC. Caveolin-1 as a biomarker of drug response and therapeutic target in association with tyrosine kinase inhibitor treatment in prostate cancer models. AACR Translational Cancer Medicine 2010, Amsterdam, The Netherlands, 3/2010.
10. Kadmon D, Sonpavde G, Jain RK, Ayala GE, Ittmann MM, Kurosaka S, Edamura K, Tabata KI, Miles BJ , Thompson TC. GLIPR1/RTVP-1 tumor suppressor gene expressed by adenovirus vector as neoadjuvant intraprostatic injection for localized high-risk prostate cancer preceding prostatectomy. 2010 ASCO Genitourinary Cancer Symposium, San Francisco, CA (#59), 3/2010.
11. Kadmon D, Sonpavde G, Jain RK, Ayala GE, Ittmann MM, Kurosaka S, Edamura K, Tabata KI, Miles BJ, Thompson TC. GLIPR1/RTVP-1 tumor suppressor gene expressed by adenovirus vector as neoadjuvant intraprostatic injection for localized high-risk prostate cancer preceding prostatectomy. 2010 ASCO Annual Meeting, Chicago, IL (#51288), 2010.
12. Langeberg WJ, Tahir SA, Feng Z, Kwon EM, Ostrander EA, Thompson TC, Stanford JL. Association of Caveolin-1 and -2 Genetic Variants and Post-treatment Serum Caveolin-1 with Prostate Cancer Risk and Outcomes. 42nd Annual SER Meeting, Anaheim, California, 6/2009.
13. Tahir SA, Park SH, Thompson TC. Caveolin-1 regulates VEGF/VEGFR2 induced angiogenic signaling. AACR 100th Annual Meeting, Denver, Colorado, 4/2009.
14. Li L, Ren C, Yang G, Abdel Fattah E, Timme TL, Goltsov AA, Park SH, Thompson TC. GLIPR1 tumor suppressor activities involve suppression of specificity protein1 and its target genes c-myc. AACR 100th Annual Meeting, Denver, Colorado, 4/2009.
15. Sonpavde G, Frolov A, Macdonell V, Hayes TG, Mims MP, Ayala GE, Wheeler TM, Thompson TC, Ittman MM, Kadmon D. Bortezomib as brief neoadjuvant therapy for localized high-risk prostate cancer followed by radical prostatectomy. 2009 ASCO Annual Meeting, Orlando, Florida, 2009.
16. Tahir SA, Yang G, Goltsov A, Watanabe M, Tabata K, and Thompson TC. Caveolin-1 uptake by endothelial cells promotes angiogenic activities and is associated with prostate cancer progression. American Association for Cancer Research, 97th Annual Meeting, Washington DC, 4/2006.
17. Goltsov A, Ren CZ, Yang G, Wang J, Li L, Timme TL, and Thompson TC. . Expression and functional analysis of PERP in mouse and human prostate cancer. American Association for Cancer Research, 97th Annual Meeting, Washington DC, 4/2006.
18. Thompson TC, Li L, Ren C, Ren CZ, Abdelfattah E-M, Goltsov A, Yang G, Wang J, Troung LD, Ittmann M, Wheeler TM, Ayala G, Kadmon D. Identification, characterization and functional analysis of RTVP-1/GLIPR-like genes – a novel p53 target gene cluster with tumor suppressor functions. 2006 Prostate Cancer Inter-SPORE Meeting, Houston, Texas, 2/2006.
19. Tabata KI, Watanabe M, Naruishi K, Satoh T, Tian WT, Wang HY, Abdelfattah E-M, Yang G, Thompson TC, Kadmon D. Therapeutic activities of IL-12 gene-modified macrophages embedded in florseal in a mouse model of residual prostate cancer. 2006 Prostate Cancer Inter-SPORE Meeting, Houston, Texas, 2/2006.
20. Thompson TC, Kadmon D, Li L, Ren CZ, Ren CH, Tahir S, Ayala G, Wheeler TM, Mims MP, Hayes T and Lynch GR. Development of RTVP-1 protein therapy for prostate cancer. 1st Place Award, 3rd Annual Cancer Center Symposium, Houston, TX, 11/2005.
21. Tabata K, Watanabe M, Naruishi K, Satoh T, Tian WT, Wang H, Abdel Fattah EM, Yang G, Kadmon K, Thompson TC. Therapeutic activities of IL-12 gene-modified macrophages embedded in Floseal in a mouse model of residual prostate cancer. 2005 Center for Cell and Gene Therapy Conference, Galveston, Texas, 11/2005.
22. Kadmon D, Tahir S, Li L, Ayala G, Wheeler TM, Frolov A, Thompson TC. The role of secreted caveolin-1 in prostate cancer progression. 12th Annual Prostate Cancer Foundation Scientific Retreat, Pheonix, Arizona, 9/2005.
23. Thompson TC, Timme TL, Egawa S, Yoshida K, Park SH, Baley PA, Slawin K, Kadmon D. Mesenchymal-epithelial interactions during prostate carcinogenesis. Fundamental Approaches to the Diagnosis and Treatment of Prostate Cancer and BPH: Proceedings of the Fifth Tokyo Symposium:105-8, 1994.
24. Thompson TC, Slawin K, Kadmon D, Park SH, Timme TL, Yoshida K, Ren C, Truong LD, Scardino PT and Eastham JA. Molecular pathways in prostate carcinogenesis. Fundamental Approaches to the Diagnosis and Treatment of Prostate Cancer and BPH: Proceedings of the Fifth Tokyo Symposium:145-9, 1994.

Book Chapters

1. Thompson TC, Tahir S, Li L, Watanabe M, Naruishi K, Yang G, Tabata K, Kurosaka S, Edamura K, Tanimoto R, Corn P, Kadmon D, Logothetis CJ, Troncoso P, Ren C, Goltsov A, Park S. Local and Distant Effects of Caveolin-1 on Prostate Cancer Progression. In: Caveolins in Cancer Pathogenesis, Prevention and Therapy. Springer: United Kingdom, 1-15, 2012. ISBN: 978-1-4614-100-3.
2. Thompson TC, Kadmon D, Arnall MF, Flanagan WF, Egawa S, Scardino PT, Park S and Merz VW. Evidence for the involvement of genetic differences and mesenchymal factors in the progression of oncogene-induced prostate cancer in reconstituted mouse prostate. In: Molecular and Cellular Biology of Prostate Cancer. Ed(s) Karr JP, Smith RG, Tindall DJ and Coffey DS. Plenum Press: New York, 1991.

Grant & Contract Support

Title: Mechanisms of Progression in Oncogene-Induced Prostate Cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 11/2007 - 10/2012
 
Title: Mechanisms of Metastasis in Experimental Prostate Cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 4/2006 - 3/2012

Last updated: 9/10/2014